research PH Dependence of the Coiled-Coil Structure of Keratin Intermediate Filament in Human Hair by 13C NMR Spectroscopy and the Mechanism of Its Disruption
Keratin structure in hair is stable at pH 5-6 but disrupts between pH 6-7.
Search
forLearn
0 / 0 results — no results
Research
5 / 457 results 
research 2-Substituted 4-(Thio)chromenone 6-O-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase
New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
research Stereocontrolled Synthesis of All Eight Stereoisomers of the Putative Anti-Androgen Cyoctol
Scientists made all eight versions of a compound called cyoctol, but found it's not an anti-androgen and it fully breaks down in the skin.
research Aromatic C-Nitrosation of a Bioactive Molecule: Nitrosation of Minoxidil
Minoxidil reacts to nitrosation 7 times more than phenol, mainly due to its -NH₂ groups, leading to the creation of N-nitrosominoxidil.
research Structural and Functional Studies of L-PGDS and SMPDL3A Enzymes in Lipid Signaling Family
L-PGDS has specific binding sites for its functions and could help in drug delivery system design.
Community Join
3 / 3 resultscommunity How to increase Pyri concentration from 0.5% to 1% wihout using more volume ( 2ml x 2 per say for example )
OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.
community The New, Improved CB-03-01/Setipiprant Group Buy
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
community Binding affinity of pyrilutamide!
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.